Aytu BioScience Inc (AYTU)vsTakeda Pharmaceutical Co Ltd ADR (TAK)
AYTU
Aytu BioScience Inc
$2.65
+0.76%
HEALTHCARE · Cap: $28.01M
TAK
Takeda Pharmaceutical Co Ltd ADR
$18.29
+1.39%
HEALTHCARE · Cap: $56.99B
Smart Verdict
WallStSmart Research — data-driven comparison
Takeda Pharmaceutical Co Ltd ADR generates 7127260% more annual revenue ($4.46T vs $62.64M). TAK leads profitability with a 2.5% profit margin vs -39.0%. TAK earns a higher WallStSmart Score of 60/100 (C).
AYTU
Avoid31
out of 100
Grade: F
TAK
Buy60
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for AYTU.
Margin of Safety
-77.5%
Fair Value
$10.30
Current Price
$18.29
$7.99 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Growing faster than its price suggests
Reasonable price relative to book value
Generating 317.5B in free cash flow
Large-cap with strong market position
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -109.2% — below average capital efficiency
Revenue declined 6.5%
4.2% revenue growth
3.3% earnings growth
ROE of 1.5% — below average capital efficiency
2.5% margin — thin
Comparative Analysis Report
WallStSmart ResearchBull Case : AYTU
The strongest argument for AYTU centers on Price/Book.
Bull Case : TAK
The strongest argument for TAK centers on PEG Ratio, Price/Book, Free Cash Flow. PEG of 0.39 suggests the stock is reasonably priced for its growth.
Bear Case : AYTU
The primary concerns for AYTU are EPS Growth, Market Cap, Return on Equity.
Bear Case : TAK
The primary concerns for TAK are Revenue Growth, EPS Growth, Return on Equity. A P/E of 82.0x leaves little room for execution misses. Thin 2.5% margins leave little buffer for downturns.
Key Dynamics to Monitor
AYTU profiles as a turnaround stock while TAK is a value play — different risk/reward profiles.
AYTU carries more volatility with a beta of 0.34 — expect wider price swings.
TAK is growing revenue faster at 4.2% — sustainability is the question.
TAK generates stronger free cash flow (317.5B), providing more financial flexibility.
Bottom Line
TAK scores higher overall (60/100 vs 31/100). Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Aytu BioScience Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Aytu Biopharma, Inc., a specialty pharmaceutical company, focuses on developing and marketing novel products in the field of hypogonadism (low testosterone levels), cough and upper respiratory symptoms, insomnia, and male infertility in the United States and internationally. The company is headquartered in Englewood, Colorado.
Takeda Pharmaceutical Co Ltd ADR
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Takeda Pharmaceutical Company Limited is engaged in the research, development, manufacture and marketing of pharmaceuticals, over-the-counter drugs and quasi-drug consumer products, and other health care products. The company is headquartered in Tokyo, Japan.
Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?